GlassScriptPhysician profile
Svetha Chunduri
NPI 1033346838
$4,324.21
in general payments reported to CMS, 2019-2025
35 companies · $1,438 in 2025
The $1,438 reported for 2025 was more than what 85% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $230 · 2020: $42.91 · 2021: $265 · 2022: $729 · 2023: $759 · 2024: $861 · 2025: $1,438.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,052 · Education: $5.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,052.00 |
| Education | $5.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $580.59 | 2021-2025 | Jynarque, Voyxact |
| Amgen INC. | $504.41 | 2023-2025 | Krystexxa, Tavneos |
| Astrazeneca Pharmaceuticals LP | $380.86 | 2021-2025 | Farxiga, Lokelma |
| Travere Therapeutics, INC. | $297.38 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $284.77 | 2021-2025 | |
| Akebia Therapeutics INC | $280.35 | 2021-2023 | Auryxia |
| Vantive US Healthcare LLC | $201.79 | 2025 | Renal - Pd, Renal - Acute |
| Glaxosmithkline, LLC. | $165.94 | 2021-2025 | Benlysta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $144.90 | 2019-2025 | Jardiance |
| Vifor Pharma, INC. | $134.69 | 2022-2023 | Korsuva, Veltassa |
| Daiichi Sankyo INC. | $132.32 | 2022-2023 | Injectafer |
| Opko Pharmaceuticals, LLC | $128.68 | 2022-2025 | Rayaldee |
| Fresenius USA Marketing, INC. | $111.03 | 2021-2023 | Korsuva, Velphoro |
| Novo Nordisk INC | $104.60 | 2024-2025 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $95.22 | 2022-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $80.24 | 2019-2023 | |
| Ardelyx, INC. | $69.23 | 2024-2025 | Ibsrela |
| Horizon Therapeutics Plc | $51.33 | 2022-2023 | Krystexxa |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $50.15 | 2025 | Voyxact |
| E.R. Squibb & Sons, L.L.C. | $49.65 | 2019-2021 | |
| Calliditas Therapeutics US INC. | $48.91 | 2022-2024 | |
| Lilly USA, LLC | $46.68 | 2023-2025 | Jardiance |
| Aurinia Pharma U.S., INC. | $44.42 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.14 | 2022-2023 | Gattex |
| Merck Sharp & Dohme LLC | $41.05 | 2019 | |
| Mylan Specialty L.P. | $40.75 | 2019 | |
| Nxstage Medical, INC. | $39.95 | 2024 | |
| Janssen Pharmaceuticals, INC | $38.21 | 2019-2020 | |
| Recor Medical INC | $25.48 | 2025 | Paradise Ultrasound Renal Denervation System |
| Ascendis Pharma Endocrinology INC | $23.59 | 2025 | Yorvipath |
| Mallinckrodt Hospital Products INC. | $20.50 | 2024 | Terlivaz |
| Ani Pharmaceuticals, INC. | $18.30 | 2025 | Purified Cortrophin Gel |
| Biomerieux INC | $17.36 | 2019 | |
| Baxter Healthcare | $16.32 | 2024 | Renal - Pd |
| Cumberland Pharmaceuticals, INC. | $13.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Svetha Chunduri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.